Morning Breakouts

Latest KFF Health News Stories

Unprepared?: Technical Snafus Foul Opening Day For Many Schools

Morning Briefing

For students who returned to school, plans were in place for temperature checks and more. School news is on children’s symptoms, vaccination schedules, future income risk and internet bills, as well.

Report: Financial Ties Between Device Makers, Teaching Hospitals

Morning Briefing

One of the authors said, “Normalizing marketing as a source of information on new drugs and devices risks teaching trainees to count on an information source that has a vested financial interest in their prescribing decisions.”

Study: 46% Of Hospitalized COVID Patients Have Acute Kidney Injury

Morning Briefing

Risk factors associated with developing AKI include older age, being a man, and having chronic kidney disease, hypertension, congestive heart failure or diabetes, according to the Center for Infectious Disease Research and Policy at the University of Minnesota.

Pfizer, BioNTech Vaccine On Track For Mid-October Approval Review: CEO

Morning Briefing

Calling the experimental vaccine his company is developing with Pfizer “near perfect,” BioNTech CEO Ugur Sahin said the pharmaceutical companies could be ready to apply for U.S. approval next month.

Glitch Silences Public On Georgia’s Plan To Cut Off Obamacare Exchange

Morning Briefing

With only a week left for the public comment period, Georgians encounter technical website issues. In other health law news: Cigna will expand in 300 more counties; and only 3 Obamacare co-ops remain.

‘Your State Should Be Open,’ Trump Tells North Carolina Supporters

Morning Briefing

During a campaign rally in Winston-Salem, North Carolina — with few masks in sight, despite a state mandate — President Donald Trump accused Gov. Roy Cooper (D-N.C.) of playing politics with the pandemic.

AstraZeneca’s Vaccine Trial Paused After Suspected Adverse Reaction

Morning Briefing

Late-stage trials of one of the front-running coronavirus vaccine candidates are on hold after a serious illness from one participant, Stat first reported. AstraZeneca said the “standard review process triggered a pause to vaccination to allow review of safety data.”